Project Grant R01AI195554
Award Date 9/1/26
Completion Date 8/31/31
Dollars Obligated $685K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Iowa City, IA 52242, USA
Similar Awards
- The National Institute of Allergy and Infectious Diseases awarded the University of Wisconsin–Madison $434,684 on February 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate how Clostridioides difficile uses glutathione metabolism during gastrointestinal infection. The research examines C. difficile's acquisition of cysteine through glutathione consumption as a metabolic strategy for pathogenesis. The work builds on preliminary data showing that C....
- The National Institute of Allergy and Infectious Diseases awarded the University of Wisconsin - Madison $1,591,093 on July 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to define the role of c-di-AMP (CDA) in Listeria monocytogenes pathogenesis. The research examines how CDA, an essential nucleotide second messenger for bacterial growth and infection, attenuates virulence in important pathogens. While CDA accumulation is widely reported to reduce...
- The National Institute of Allergy and Infectious Diseases awarded the University of Notre Dame $769,354 on May 22, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to elucidate spore germination machinery in Clostridioides difficile and optimize a class of antibiotics called oxadiazoles as spore germination inhibitors. The research addresses recurrent C. difficile infections, which occur in approximately 25 percent of patients and represent a significant source of...
- The National Institute of Allergy and Infectious Diseases awarded the University of Wisconsin–Madison $753,899 on February 2, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate the effects of butyrate on Clostridioides difficile fitness and pathogenesis. The research addresses mechanisms by which butyrate, a microbiome-host co-metabolite influenced by dietary fiber intake, impacts C. difficile infection. The project builds on preliminary data and...
- The National Institute of Allergy and Infectious Diseases (NIAID), part of the Department of Health and Human Services National Institutes of Health, awarded $437,541 to Virginia Polytechnic Institute & State University on February 2, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop antisense therapeutics targeting Clostridioides difficile infection. The research focuses on designing antisense oligomers, including peptide nucleic acids, to suppress...
- The National Institute of Allergy and Infectious Diseases awarded $182,424 to Trustees of Tufts College (doing business as Tufts University School of Medicine) on October 24, 2025, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to support research on the effect of epithelium association and toxin gene expression on Clostridioides difficile disease severity. The research addresses the mechanisms driving disease severity in C. difficile infection (CDI), the most common...
- The National Institute of Allergy and Infectious Diseases awarded the Regents of the University of Minnesota $529,512 on February 20, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to define the mechanism of intoxication of the Clostridioides difficile transferase. The research uses cryogenic electron microscopy, biochemical and biophysical assays, and cellular biology to address two key questions: how toxin assembly is regulated and triggered, and what...
- The National Institute of Allergy and Infectious Diseases awarded Trustees of Tufts College (doing business as Tufts University School of Medicine) $151,040 on January 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to identify and characterize the unique cell division machinery of Clostridioides difficile, a major nosocomial pathogen. The research addresses a critical gap in understanding bacterial cell division. Unlike model organisms studied over decades,...
- The National Institute of Allergy and Infectious Diseases awarded The University of Iowa $427,625 on February 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to support research on how TRAF3 regulates CD4 T cell differentiation and function during chronic infections. The research employs single-cell technologies and cutting-edge genomic and epigenetic approaches—including single-cell RNA sequencing—to dissect how TRAF3 integrates T cell receptor, cytokine, and...
- The National Institute of Allergy and Infectious Diseases awarded $430,024 to the University of Pittsburgh on July 8, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate intestinal interactions between Clostridioides difficile and Clostridium perfringens and their impact on gastrointestinal disease pathology. The research addresses the epidemiologic association between these two clostridial pathogens, which frequently co-occur in diarrheic feces of...